Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. Click here to read an ...
Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly alternative.
This approval will further enhance Darzalex’s penetration of the multiple myeloma market.